Response to 'Psoriasis patients' preference for an aerosol foam topical formulation' by Vender R et al

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):e401-e402. doi: 10.1111/jdv.14985. Epub 2018 May 7.

Authors

C-H Hong¹, K A Papp², K W Lophaven³, P Skallerup³, S Philipp⁴

Affiliations

¹ Department of Dermatology and Skin Science and Probity Medical Research, University of British Columbia, Surrey, BC, Canada.
² Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada.
³ LEO Pharma A/S, Ballerup, Denmark.
⁴ Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.

PMID: 29633353
DOI: 10.1111/jdv.14985

No abstract available

Publication types

Letter
Comment

MeSH terms

Aerosols
Betamethasone
Humans
Patient Preference*
Psoriasis*

Substances

Aerosols
Betamethasone